(Q46781809)

25 December 2017

title

The effect of high-dose simvastatin on triglyceride-rich lipoprotein metabolism in patients with type 2 diabetes mellitus (English)

1 reference

25 December 2017

1 reference

1 reference

1 reference

1 reference

3

Bruce W Patterson

1 reference

25 December 2017

author name string

William L Isley

series ordinal

1

1 reference

25 December 2017

John M Miles

series ordinal

2

1 reference

25 December 2017

William S Harris

series ordinal

4

1 reference

25 December 2017

publication date

28 October 2005

1 reference

25 December 2017

Journal of Lipid Research

published in

1 reference

25 December 2017

volume

47

1 reference

25 December 2017

issue

1

1 reference

25 December 2017

page(s)

193-200

1 reference

25 December 2017

Splanchnic metabolism of free fatty acids and production of triglycerides of very low density lipoproteins in normotriglyceridemic and hypertriglyceridemic humans

cites work

1 reference

https://api.crossref.org/works/10.1194%2FJLR.M500387-JLR200

Interaction between free fatty acids and insulin in the acute control of very low density lipoprotein production in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.M500387-JLR200

Lipoprotein physiology in nondiabetic and diabetic states. Relationship to atherogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.M500387-JLR200

Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.M500387-JLR200

Mevinolin and colestipol stimulate receptor-mediated clearance of low density lipoprotein from plasma in familial hypercholesterolemia heterozygotes

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.M500387-JLR200

Comparisons of effects of statins (atorvastatin, fluvastatin, lovastatin, pravastatin, and simvastatin) on fasting and postprandial lipoproteins in patients with coronary heart disease versus control subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.M500387-JLR200

MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.M500387-JLR200

Apolipoprotein B metabolism in humans: studies with stable isotope-labeled amino acid precursors

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.M500387-JLR200

Effects of atorvastatin versus fenofibrate on apoB-100 and apoA-I kinetics in mixed hyperlipidemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.M500387-JLR200

Atorvastatin treatment induced peroxisome proliferator-activated receptor alpha expression and decreased plasma nonesterified fatty acids and liver triglyceride in fructose-fed rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.M500387-JLR200

Prolonged inhibition of cholesterol synthesis by atorvastatin inhibits apo B-100 and triglyceride secretion from HepG2 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.M500387-JLR200

Different effect of simvastatin and atorvastatin on key enzymes involved in VLDL synthesis and catabolism in high fat/cholesterol fed rabbits

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.M500387-JLR200

Effect of atorvastatin, simvastatin, and lovastatin on the metabolism of cholesterol and triacylglycerides in HepG2 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.M500387-JLR200

Atorvastatin improves diabetic dyslipidemia and increases lipoprotein lipase activity in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.M500387-JLR200

Effect of simvastatin (MK-733) on plasma triacylglycerol levels in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.M500387-JLR200

Effect of hypolipidemic drugs on key enzyme activities related to lipid metabolism in normolipidemic rabbits

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.M500387-JLR200

Effect of atorvastatin treatment on lipoprotein lipase mass in the pre-heparin plasma in Japanese hyperlipidemic subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.M500387-JLR200

Effects of atorvastatin on the clearance of triglyceride-rich lipoproteins in familial combined hyperlipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.M500387-JLR200

Effect of atorvastatin on apolipoprotein B100 containing lipoprotein metabolism in type-2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.M500387-JLR200

Differential regulation of lipoprotein kinetics by atorvastatin and fenofibrate in subjects with the metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.M500387-JLR200

Exogenous and endogenous postprandial lipid abnormalities in type 2 diabetic patients with optimal blood glucose control and optimal fasting triglyceride levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.M500387-JLR200

Contribution of apo CIII reduction to the greater effect of 12-week micronized fenofibrate than atorvastatin therapy on triglyceride levels and LDL size in dyslipidemic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.M500387-JLR200

3-Hydroxy-3-methylglutaryl CoA reductase inhibitors reduce serum triglyceride levels through modulation of apolipoprotein C-III and lipoprotein lipase

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.M500387-JLR200

Induction of lipoprotein lipase gene expression in 3T3-L1 preadipocytes by atorvastatin, a cholesterol- and triglyceride-lowering drug

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.M500387-JLR200

Statin induction of liver fatty acid-binding protein (L-FABP) gene expression is peroxisome proliferator-activated receptor-alpha-dependent

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.M500387-JLR200

Regulation of peroxisome proliferator-activated receptor gamma expression by adipocyte differentiation and determination factor 1/sterol regulatory element binding protein 1: implications for adipocyte differentiation and metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.M500387-JLR200

Influence of atorvastatin and simvastatin on apolipoprotein B metabolism in moderate combined hyperlipidemic subjects with low VLDL and LDL fractional clearance rates

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.M500387-JLR200

Modification of low density lipoprotein by advanced glycation end products contributes to the dyslipidemia of diabetes and renal insufficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.M500387-JLR200

VLDL-triglyceride kinetics during hyperglycemia-hyperinsulinemia: effects of sex and obesity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.M500387-JLR200

Effect of weight loss on VLDL-triglyceride and apoB-100 kinetics in women with abdominal obesity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.M500387-JLR200

10.1194/JLR.M500387-JLR200

21 January 2018

Identifiers

DOI

1 reference

25 December 2017

PubMed ID

16258165

1 reference

25 December 2017